Viyash Scientific Posts 52% PAT Surge Post-Amalgamation

OTHER
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Viyash Scientific Posts 52% PAT Surge Post-Amalgamation
Overview

Viyash Scientific (formerly Sequent) reported a 52.05% YoY jump in consolidated PAT to ₹503.30 Cr for Q3 FY2026, with revenue up 10.91%. Consolidated revenue grew 11.43% to ₹25,003.50 Cr for nine months. However, standalone PAT dipped 14.99% for the nine-month period, impacted by significant amalgamation expenses totaling ₹412.60 Cr on a standalone basis. The amalgamation scheme became effective December 16, 2025, with restated comparative figures.

📉 The Financial Deep Dive

The Numbers:
On a consolidated basis, Viyash Scientific Limited (formerly Sequent Scientific Limited) delivered robust financial results for the third quarter of FY2026.

  • Consolidated Revenue for Q3 FY2026: ₹8,584.10 Cr, a year-on-year (YoY) increase of +10.91% compared to ₹7,740.30 Cr in Q3 FY2025.

  • Consolidated Profit After Tax (PAT) for Q3 FY2026: ₹503.30 Cr, marking a significant YoY growth of +52.05% from ₹331.00 Cr in the prior year's quarter.

For the nine months ended December 31, 2025, the consolidated performance remained strong:
  • Consolidated Revenue for 9M FY2026: ₹25,003.50 Cr, up +11.43% YoY.

  • Consolidated PAT for 9M FY2026: ₹2,679.90 Cr, an increase of +19.76% YoY from ₹2,237.80 Cr.

Standalone figures, however, showed a mixed performance, heavily influenced by one-off expenses:
  • Standalone PAT for Q3 FY2026: ₹584.90 Cr, a YoY increase of +39.48%.

  • Standalone PAT for 9M FY2026: ₹674.70 Cr, a YoY decrease of -14.99%.

The Quality:
Consolidated PAT growth significantly outpaced revenue growth, indicating improved profitability and operational leverage following the amalgamation. Exceptional items resulted in a consolidated loss of ₹141.20 Cr and a standalone loss of ₹412.60 Cr, primarily due to amalgamation expenses. These one-off costs significantly impacted standalone PAT. Consolidated 'Other Income' of ₹139.80 Cr, including a ₹43 Cr profit from asset sales, provided an additional boost to the consolidated bottom line.

The Grill:
This filing is a factual announcement of financial results and board meeting outcomes. It does not contain a transcript of an analyst call or management commentary that would be subject to aggressive questioning. Therefore, no specific 'grill' analysis is applicable here.

🚩 Risks & Outlook

  • Specific Risks: The substantial year-on-year decline in standalone PAT for the nine-month period warrants deeper scrutiny into the underlying operational performance, distinct from the one-off amalgamation costs. Potential integration challenges post-amalgamation could also pose execution risks.

  • The Forward View: Investors should focus on the company's ability to sustain its strong consolidated growth trajectory in the upcoming quarters. Key watchpoints will include the resolution of amalgamation-related costs and the normalization of standalone profitability, alongside the overall strategic benefits materializing from the merger.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.